Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
biotech
boston blog main
boston top stories
ipo
5
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
5
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
vc
5
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
venture capital
wisconsin blog main
wisconsin top stories
biogen
celgene
fda
gene editing
gene therapy
novartis
biomarin pharmaceutical
cancer
car-t
commissioner
What
bio
roundup
new
ipo
medicines
activity
aiming
allogene
ambys
approvals
becker
big
billions
biogen
biopharma
biotech
cancer
car
celgene
clamped
colleagues
control
covid
crispr
deadly
deal
debuted
delays
developing
diseases
diversity
dollars
eaton
economic
exome
fast
fda
formed
future
gene
Language
unset
Current search:
ipo
×
vc
×
" new york top stories "
×
photo
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?